GoodRx Says Q1, Q2 2026 Financials Can No Longer Be Relied Upon After Understating Pharma Direct Revenue By $29.773M; Expects Material Weakness

Benzinga · 1d ago

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001809519/000180951926000184/gdrx-20261027.htm